Tradestie Institutional Equity Comparison Engine

TRVI vs DMAC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Momentum & Technical, Options & Structure while TRVI counters with relative strength in Growth & Margin. Fundamentally, TRVI trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, TRVI sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
TRVI N/M vs DMAC N/M Fwd P/E
Growth & Margin Winner TRVI
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner DMAC
1Y +16.4% vs +55.3% ยท 52W Pos 34% vs 55%
Options & Structure Winner DMAC
CONSOLIDATION (8th %ile IV) vs SURGE (14th %ile IV)
TRVI NASDAQ
Trevi Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$13.34
-2.27% 1D
Market Cap $1.9B
1M Return +12.29%
1Y Return +16.4%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 41.0 Fund 52.0 Flow 64.0 Mom 54.0
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TRVI +16.4% DMAC +55.26% Spread: +38.86 pp (DMAC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TRVI TTM Op. Margin: 0.0% DMAC TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TRVI vs DMAC. Trailing 12-month operating profitability (TRVI 0.0% vs DMAC 0.0%) and valuation multiples (TRVI N/M vs DMAC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TRVI (3) vs DMAC (2)
Institutional Metric TRVI DMAC Criterion Row Winner
Market Capitalization Scale $1.9B $503.1M Larger Scale TRVI
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -24.7% -114.6% Higher ROE TRVI
52-Week Range Position Momentum 34% ($10โ€“$20) 55% ($5โ€“$11) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 1.49ฮฒ ยท 76% Vol 1.74ฮฒ ยท 98% Vol Lower Realized Risk TRVI
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite DMAC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TRVI vs DMAC Buy Guide
TRVI CONSOLIDATION
103d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live TRVI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TRVI nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.